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Abstract 
Background 
Epidemiological data indicate that obesity is a risk factor for asthma, but scientific literature 
is still debating the association between changes in body mass index (BMI) and airway 
hyperresponsiveness (AHR). 
Methods 
This study aimed at evaluating the influence of BMI on AHR, in outpatients with symptoms 
suggestive of asthma. 
4,217 consecutive adult subjects (2,439 M; mean age: 38.2±14.9 yrs; median FEV1 % 
predicted: 100 [IQR:91.88-107.97] and FEV1/FVC % predicted: 85.77 % [IQR:81.1-90.05]), 
performed a methacholine challenge test for suspected asthma. Subjects with PD20 < 200 or 
200 < PD20 < 800 or PD20 > 800 were considered affected by severe, moderate or mild AHR, 
respectively.. 
Results 
A total of 2,520 subjects (60 % of all cases) had a PD20 < 3,200 μg, with a median PD20 of 
366 μg [IQR:168–1010.5]; 759, 997 and 764 patients were affected by mild, moderate and 
severe AHR, respectively. BMI was not associated with increasing AHR in males. On the 
contrary, obese females were at risk for AHR only when those with moderate AHR were 
considered (OR: 1.772 [1.250-2.512], p = 0.001). A significant reduction of FEV1/FVC for 
unit of BMI increase was found in moderate AHR, both in males (β = −0.255; p =0.023) and 
in females (β = −0.451; p =0.017). 
Conclusions 
Our findings indicate that obesity influences AHR only in females with a moderate AHR 
level. This influence may be mediated by obesity-associated changes in baseline lung 
function. 
Keywords 
Airway hyperresponsiveness, asthma, body mass index, males and females, methacholine 
test, obesity 
Background 
A body of evidence has clearly demonstrated an association between obesity and asthma. In 
fact, obesity increases the risk of asthma and contributes to the occurrence of a more difficult-
to-control phenotype of the disease [1]. Likely, this relationship is mediated by obesity-
associated changes in lung function [1-3]. Indeed, the extra-pulmonary restrictive syndrome 
impairs the airway distensibility and causes a reduction in peripheral airway diameter which 
potentially increases airway hyperresponsiveness (AHR). In addition, hormonal and 
inflammatory factors, directly related to the adipose tissue, may influence some asthmatic 
phenotypes [1-3]. The adipose tissue expresses a number of pro-inflammatory molecules, 
such as leptin, tumour necrosis factor α (TNF-α), interleukin 6 (IL-6), transforming growth 
factor β1 (TGF- β1), adiponectin and C-reactive protein, which have been shown to modulate 
the airway inflammatory response thus promoting asthma [1-3]. 
To explain the mechanism underlying the relationship between obesity and asthma, the 
association between body mass index (BMI) and AHR has become the field of interest, 
leading, however, to conflicting results [1-3]. Several studies have shown a significant 
association between BMI and AHR [2,4-7], whereas others have failed to confirm this 
relationship [8-11]. An additional controversial issue is the different role of BMI with regard 
to gender. In some studies, specifically addressing the influence of gender, the relationship 
between BMI and asthma appeared to be significant only in females, whereas other 
investigations did not observe gender-associated differences [2,4,6,7,12,13]. The lack of 
definite data on the association between BMI and asthma may be due to several factors, such 
as the influence of asthma medications, the inclusion of relatively small numbers of patients 
and uncorrected asthma diagnosis. The use of inhaled corticosteroids, bronchodilators and 
anti-leukotriens can influence bronchial provocation test results [14,15]. Furthermore, when a 
higher cut-off value is used to define a positive bronchial provocation test, the asthma 
diagnosis may be overestimated [16] and this can obviously influence the outcome of the 
relationship with BMI. 
To the best of our knowledge, there are no data specifically addressing the relationship 
between BMI and the different levels of bronchial hyperresponsiveness. With the assumption 
that there may be an association between BMI and asthma, we hypothesized that this should 
be different in the various AHR levels (i.e. mild, moderate and severe AHR). We therefore 
postulated that such a relationship should be more significant in subjects with a severe AHR 
rather than in subjects with a mild or moderate AHR. 
Our retrospective study aimed at exploring in a large cohort of individuals whether there may 
be an association between BMI and AHR and if this association might be different in the 
various AHR levels. We also evaluated whether it may be affected by a possible relationship 
between BMI and baseline pulmonary function. In order to limit the influence of treatment, 
only subjects not taking asthma medications regularly were included in the study. 
Methods 
Subjects 
A total of 4,217 consecutive adult subjects (2,439 M; mean age 38±14.9 yrs; median FEV1% 
predicted 100 % [IQR: 91.88-107.97] and FEV1/FVC% 85.77 % [IQR: 81.1-90.05]), who had 
performed a methacholine (Mch) bronchoprovocation test, were included. Subjects had been 
visited in the Pneumology Departments of Grosseto and ArezzoHospitals (between 2000 and 
2010) to confirm an asthma diagnosis. All subjects showed normal baseline lung function and 
had symptoms suggestive of asthma (unexplained episodes of cough and/or wheezing and/or 
dyspnea on exertion). FEV1, FEV1/FVC, FVC, FEF25-75 were obtained at baseline (pre-
Mchtest). The PD20FEV1 was calculated for each bronchoprovocation test and represented the 
main outcome of the study. Smoking habits, age, sex and BMI were also recorded for 
analysis. The use of data for the purpose of the study was approved by the local Ethic 
Committees. 
None of the subjects was under regular treatment for asthma at the time of the test. Subjects, 
who had taken drugs when required, were asked to refrain from taking any medications prior 
to the Mchbronchoprovocation test. β2-agonist bronchodilators and inhaled or systemic 
corticosteroids were withheld 24 hours and 3 weeks before the test respectively, while 
antihistamines were stopped at least 10 days before the test. None of the subjects had suffered 
from airway infections or asthma exacerbations in the four weeks prior to the test. BMI was 
calculated by dividing the weight in kilograms by the square of the height in metres (kg/m
2
). 
According to the WHO classification, a BMI of < 18.5 kg/m
2
 describes a condition of 
underweight, 18.5-24.9 kg/m
2
 normal weight, 25–29.9 kg/m2 overweight and ≥ 30 kg/m2 
obesity. 
Mchbronchoprovocation test 
The Mch bronchoprovocation test was performed by using a dosimeter method [17]. The 
same instrument and method were used both in Grosseto and Arezzo in the years 2000–2010. 
Mchsulphate was supplied by Lofarma (Milan, Italy) and given in aerosol form using an 
MEFAR MB3 dosimeter (output: 9 μL/puff; MEFAR Elettromedicali Brescia, Italy) with an 
MB2 ampoule model. Buffer and Mch were diluted with distilled water and then two 
different progressive Mch solutions were obtained: an ampoule containing a Mch 
concentration of 4 mg/ml (40 μg inhalation dose) and another with 40 mg/ml (400 μg 
inhalation dose). The buffer solution was the first to be administered, followed by 40 μg of 
methacholine, increasing the doses until PD20FEV1 was obtained or until the maximum dose 
of Mch was reached. FEV1 was measured after inhaling 40, 80, 120, 240, 400, 800, 1,600, 
2,400 and 3,200 μg of cumulative Mch doses, respectively. At the end of exhalation, during 
tidal breathing, patients inhaled Mch slowly and deeply from the nebulizer in 5 seconds and 
then held their breath for 5 additional seconds. The test was interrupted if a fall in FEV1>10 
% occurred with the buffer solution. The interval between two consecutive steps was 2 
minutes. FEV1 was measured at 30 and 90 seconds after nebulization. An acceptable quality 
of FEV1 was achieved at each step. No more than two maneuvers after each dose were 
allowed and the highest FEV1 value was considered. AHR was defined by a 20 % fall in 
FEV1 from the reference value (see below) obtained with a cumulative Mch dose < 3,200 μg. 
Subjects who did not achieve a 20 % fall in FEV1 with a Mch dose of 3,200 μg were 
classified as normoreactive. 
Subjects with PD20 ≤ 200, 200 < PD20 ≤ 800 and PD20 > 800 were arbitrarily considered as 
affected by severe, moderate and mild AHR respectively, with the purpose of evaluating the 
effects of BMI on the different levels of AHR. 
Lung function was measured with a HP 47120E Pulmonary System Desk spirometer (Hewlett 
Packard, Waltham, Massachusetts - USA). At baseline, FEV1 and FVC were expressed as 
percentages of the predicted values, whereas FEV1/FVC was reported only as a ratio 
(reference equation: CECA, 1971). The PD20 FEV1 was assessed by linear interpolation of 
the dose–response curves. The FEV1 measured before administering the buffer solution was 
used as the baseline value, while the FEV1 measured after inhaling the buffer solution was 
used as reference value to calculate FEV1 decrease and thus PD20. 
Statistical analysis 
Categorical variables were expressed as number of cases and percentages. Continuous 
variables were expressed as mean values and standard deviations or median values and 
interquartile range (IQR – 25° and 75° quartiles) according to whether they were normally 
distributed. Nonparametric or parametric tests were performed accordingly. Comparisons of 
qualitative and quantitative variables among groups were conducted by the chi-square test or 
the ANOVA one way test, respectively. Moreover, the Bonferroni test was used for multiple 
comparisons. The logistic binary regression model was applied separately in males and in 
females to evaluate independent risk factors for AHR. In order to evaluate the risk of the 
independent variables in the various levels of AHR (severe, moderate and mild), three 
logistic regression models were performed (both in males and females), considering subjects 
either with PD20>800 μg, or with PD20>200 and <800 μg, or with PD20<200 μg and 
comparing them with normal subjects. In these models, BMI was considered as qualitative 
variables, i.e. underweight, normal weight, overweight and obese subjects. The linear 
regression model was performed to evaluate whether a relationship existed between BMI and 
pulmonary function (FEV1, FVC, FEV1/FVC) in all degrees of AHR, adjusted for age, sex 
and smoking habits. P values < 0.05 were considered statistically significant. The statistical 
packages SPSS (16.0) was used for analysis. 
Results 
The subjects' characteristics are described in Table 1. FEV1 and FVC measured in 
underweight subjects were lower in comparison with those observed in normal weight, 
overweight and obese ones. FEV1/FVC was lower in overweight and obese patients if 
compared with normal weight individuals. On the contrary, FEV1/FVC were higher in 
underweight people. Hyperresponsive subjects (defined by a PD20< 3200 μg) were 2,520 (60 
% of the total), with a median PD20 of 366 μg [IQR: 168–1010.5]. In details, 759 had mild, 
997 moderate and 764 severe AHR. Gender was equally distributed among the AHR groups. 
Both prevalence (Figure 1) and magnitude of AHR (Table 2 and Table 3) were similar among 
the different levels of BMI (underweight, normal weight, overweight and obese), in males 
and females and in different categories of subjects e.g. different ages, smokers, non-smokers 
and various AHR levels. 
Table 1 Characteristics at baseline of 4,217 patients who underwent a methacholine challenge test 
 Underweight Normal weight Overweight Obese Total p 
N. patients (M/F) 87 (20/67)* 2255 (1087/1168)*° 1300 (757/543)*° 
#
 575 (205/370)*° 
#
 4217 (2069/2148) 0.0001 
Age 29±11* 34±13*° 42±15*° 
#
 47±15*° 
#
 38±15 0.0001 
1
Current mokers (%) 24 (31.2 %) 490 (24.9 %) 205 (17.6 %) 72 (14.3 %) 791 (21.3 %) 0.0001 
1
Ex smokers (%) 1 (1.3 %) 101 (5.1 %) 127 (10.9 %) 65 (12.9 %) 294 (7.9 %) 
1
Non-Smokers 52 (67.5 %) 1376 (70.0 %) 831 (71.5 %) 367 (72.8 %) 2626 (70.8 %) 
Patients with normal reactivity 34 (39.1 %) 903 (40.0 %) 530 (40.8 %) 230 (40.0 %) 1697 (40.2 %) 0.969 
Patients with PD20<3200 μg 53 (60.9 %) 1352 (60.0 %) 770 (59.2 %) 345 (60.0 %) 2520 (59.8 %) 
FEV1% of predicted 96.96 [87.43-103.43]*° 
#
 100 [92.34-107.83]* 100 [91.79- 108.60]° 100 [90.26- 107.87]
#
 100 [91.88-107.97] 0.007 
FVC % of predicted 92.06 [86.74-98.54]*° 
#
 98.84 [91.15-107.33]* 100.0 [92.16-108.36]° 99.77 [90.49-107.85]
#
 99.11 [91.21-107.60] 0.0001 
FEV1/FVC 90.04 [84.94-95.03]*° 
#
 86.79 [81.80-91.56]* 84.69 [80.09-88.53]° 84.10 [80.76-88.20]
#
 85.77 [81.10-90.05] 0.0001 
BMI 17.61±1.75* 22.17±1.71*° 27.10±1.39*° 
#
 33.53±3.90*° 
#
 25.14±4.58 0.0001 
BMI, body mass index;FEV1, forced expiratory volume in one second; FVC, forced vital capacity. The continuous variables are median (interquartile range [IQR]) or 
mean ± standard deviation and categorical values are expressed as number of cases (percentages). Mean comparisons were made by using the ANOVA test; median 
comparisons were made by using the Kruskal-Wallis test; proportion comparisons were made by using the χ2 test; post-hoc analysis was made by the Bonferroni 
correction.*° 
#
 statistically significant differences between groups when they were compared. 
1
valuated on 3,711 subjects whose smoking history was known. 
 
 
 
Figure 1 Percentages of subjects with airways hyperresponsiveness defined by a PD20 < 3,200 μg in males and females according to weight, 
subdivided in the various categories taken into account. Comparisons were made by using the χ2 test 
 
Table 2 Median PD20 [IQR] values measured in males subdivided into various sub-groups taken into account 
 Underweight Normal weight Overweight Obese Total p 
Aged 18–26 years (n 556) 656 [366–1589] 361 [169–852] 346 [166–846] 193 [146–356] 351 [168–848] 0.058 
Aged 27–44 years old (n 394) 312 [312–312] 370 [150–981] 319 [165–1039] 354 [213–1032] 341 [161–1027] 0.871 
Age≥45 years (n 228) - 320 [104–1172] 360 [178–1133] 436 [277–903] 368 [180–1110] 0.343 
Severe AHR (PD20≤200) (n 367) 117 [117–117] 95 [67–143] 115 [61–170] 116 [75–126] 105 [65–158] 0.159 
Moderate AHR (PD20>200 and ≤800) (n 471) 377 [355–637] 377 [291–584] 351 [290–498] 353 [272–490] 357 [290–546] 0.294 
Mild AHR (PD20>800) (n 340) 1855 [1322–3135] 1496 [1100–2097] 1530 [1105–2020] 1125 [1032–2167] 1437 [1094–2061] 0.142 
Non-smokers (n 794) 507 [355–674] 343 [156–896] 343 [170–1036] 340 [192–825] 345 [168–944] 0.688 
Smokers (n 248) 1589 [1322–1855] 547 [210–1060] 322 [169–1113] 352 [272–716] 442 [194–1072] 0.102 
Total (n 1178) 637 [355–1322] 360 [156–928] 343 [169–1045] 355 [203–825] 353 [168–963] 0.555 
AHR, Airways hyperresponsiveness. Comparisons were made by using the Kruskal-Wallis test. 
Table 3 Median PD20 [IQR] values measured in females subdivided into various sub-groups taken into account 
 Underweight Normal weight Overweight Obesity Total p 
Aged 18–26 years (n 211) 574 [75–1257] 371 [139–930] 330 [157–1491] 262 [137–663] 350 [140–1003] 0.763 
Aged 27–44 years (n 605) 874 [213–1366] 455 [171–1101] 322 [159–697] 308 [155–917] 384 [165–1046] 0.065 
Age≥45 years (n 526) 115 [96–373] 563 [197–1238] 384 [170–1063] 366 [205–848] 437 [179–1072] 0.160 
Severe AHR (PD20≤200) (n 400) 59 [40–96] 94 [56–146] 107 [52–157] 105 [52–156] 98 [54–149] 0.125 
Moderate AHR (PD20>200 and ≤800) (n 523) 369 [317–568] 437 [298–605] 363 [287–562] 355 [295–528] 383 [295–576] 0.858 
Mild AHR (PD20>800) (n 419) 1366 [1176–1805] 1447 [1072–2026] 1484 [1097–2112] 1473 [1203–1948] 1451 [1097–2015] 0.064 
Non-smokers (n 889) 468 [99–1169] 473 [157–1109] 382 [165–1077] 359 [180–814] 396 [161–1072] 0.765 
Smokers (n 273) 1132 [72–1521] 502 [172–986] 332 [151–647] 321 [203–818] 407 [160–980] 0.449 
Total (n 1342) 568 [108–1271] 490 [161–1077] 354 [160–964] 352 [179–817] 387 [165–1052] 0.359 
AHR, Airways hyperresponsiveness. Comparisons were made by using the Kruskal-Wallis test. 
We therefore assessed whether BMI was associated with the AHR level (Spearman 
correlation), as expressed by the PD20, in specific subgroups (Table 4), in females, a 
significantly negative correlation between BMI and AHR resulted in all hyperresponsive 
subjects aged 27–44 years (r = −0.113). This relationship was likely caused by the 
significantly negative association detected in females with moderate AHR (r = −0.210). A 
similar relationship was detected in younger (r = −0.257) and in non-smokers (r = −0.116) 
females with moderate AHR. Interestingly, a highly positive significant correlation between 
BMI and PD20 was observed in underweight females with moderate AHR (r = 0.587), which 
probably influences the positive significant association in the entire group of underweight 
females. 
Table 4 Spearman and partial correlation (r) between PD20 and BMI in males and 
females with different AHR levels divided into various sub-groups 
 All males 
with 
AHR 
All 
females 
with 
AHR 
Males 
with 
severe 
AHR 
Females 
with 
severe 
AHR 
Males 
with 
moderate 
AHR 
Females 
with 
moderate 
AHR 
Males with 
mild AHR 
Females 
with mild 
AHR 
All subjects with AHR (n. 
2520) 
−0.003 −0.033 0.105* 0.067 −0.086 −0.115 −0.041 0.029 
Aged 18–26 years (n. 767) −0.038 −0.072 0.074 0.229 −0.066 −0.257* −0.113 0.030 
Aged 27–44 years (n. 999) −0.031 −0.113° 0.062 −0.082 −0.135 −0.210
#
 −0.133 −0.088 
Age≥45 years (n. 754) 0.092 −0.001 0.268* 0.076 0.092 −0.091 0.067 0.025 
Non-smokers (n. 1683) 0.016 −0.012 0.101 0.069 −0.032 −0.116* −0.084 −0.016 
Smokers (n. 521) −0.082 −0.057 0.185 0.216* −0.239* −0.111 0.099 0.048 
Underweight (n. 53) −0.30 0.288 - −0.115 −0.100 0.587* −0.500 −0.248 
Normal weight (n. 1352) 0.011 −0.004 −0.024 −0.011 0.030 −0.061 −0.049 −0.016 
Overweight (n. 770) 0.015 0.120* 0.038 0.070 −0.013 0.115 0.102 0.021 
Obese (n. 345) −0.065 0.098 0.018 −0.177 0.087 −0.097 −0.154 −0.044 
All subjects with AHR
1
 (n 
2198) 
−0.060 −0.050 0.104 0.042 −0.088 −0.161# −0.113* −0.032 
Subjects with AHR = PD20 < 3200 μg; Severe AHR = PD20 ≤ 200 μg; moderate AHR = PD20 
> 200 and ≤ 800 μg; mild AHR = PD20 > 800 μg; *p < 0.05; °p < 0.01; 
#
p < 0.001; 
1
correct 
for age, smoking habits, FEV1 and FVC, calculated on subjects where the smoking history 
was known. 
In males, a strong inverse correlation was observed in the mild underweight group between 
BMI and PD20 (r = −0.500). A similar significant relationship was seen in smokers with 
moderate AHR (r = −0.239). Positive associations between BMI and PD20 were observed in 
individuals with severe AHR (r = 0.105) and in particular in those aged over 45 years (r = 
0.268). When a partial correlation (adjusted for age, FEV1, FVC and smoking habits) was 
applied, significantly negative relationships between BMI and PD20 were confirmed in 
females with moderate AHR and males with mild AHR (Table 4). 
The logistic regression model showed that in hyperreactive males the underweight condition 
appeared to be the protective factor against AHR (Table 5), although the relationship was 
weak (p = 0.047). In females, BMI was held as a risk factor for AHR only in obese subjects 
with moderate AHR (OR: 1.772 [1.250-2.512], p = 0.001) (Table 6). Age acted as a 
protective factor for AHR in all males (Table 5) and only in females (Table 6) with moderate 
and severe AHR groups. Smoking habit was a significant risk factor in females for all 
different levels of AHR, but not in males. FEV1 and FVC were risk and protective factors 
respectively for AHR both in males and females in all AHR levels. 
Table 5 Logistic binary regression model to evaluate the AHR risk of the various considered covariates in males with different levels of 
airways hyperresponsiveness (compared to normal subjects) 
 All AHR subjects
a
 Mild AHR
a
 Moderate AHR
a
 Severe AHR
a
 
 OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI P 
Aged 27–44 years)b 0.627 0.496-0.793 0.0001 0.757 0.545-1.051 0.097 0.605 0.450-0.813 0.001 0.572 0.407-0.804 0.001 
Age ≥ 45 yearsb 0.453 0.344-0.596 0.0001 0.672 0.461-0.979 0.038 0.359 0.247-0.523 0.0001 0.408 0.272-0.610 0.0001 
Smoking
c
 1.101 0.869-1.395 0.424 1.212 0.877-1.675 0.244 1.147 0.854-1.540 0.361 0.874 0.613-1.245 0.455 
FEV1 % of predicted 0.934 0.921-0.948 0.0001 0.969 0.950-0.989 0.002 0.936 0.919-0.954 0.0001 0.899 0.880-0.918 0.0001 
FVC % of predicted 1.039 1.025-1.054 0.0001 1.009 0.990-1.029 0.360 1.043 1.025-1.062 0.0001 1.066 1.045-1.087 0.0001 
Winter
d
 1.104 0.841-1.448 0.477 1.253 0.860-1.824 0.240 0.988 0.695-1.404 0.945 1.185 0.800-1.757 0.398 
Spring
d
 1.103 0.849-1.434 0.463 1.106 0.765-1.599 0.592 1.157 0.829-1.614 0.392 1.229 0.840-1.799 0.289 
Summer
d
 0.886 0.665-1.181 0.410 0.932 0.620-1.399 0.733 0.979 0.680-1.411 0.910 0.793 0.515-1.223 0.295 
Underweight
ef
 0.384 0.149-0.988 0.047 0.466 0.125-1.734 0.255 0.596 0.198-1.791 0.357 - - - 
Overweight
ef
 1.247 0.999-1.557 0.051 1.200 0.883-1.632 0.244 1.099 0.823-1.467 0.522 1.366 0.993-1.879 0.055 
Obese
ef
 1.059 0.748-1.501 0.746 0.924 0.559-1.527 0.757 1.435 0.928-2.220 0.105 0.885 0.520-1.508 0.654 
Subjects with AHR = PD20 < 3200 μg; Severe AHR = PD20 ≤ 200 μg; moderate AHR = PD20 > 200 and ≤ 800 μg; mild AHR = PD20 > 800 μg; 
a
vs subjects with normal reactivity (without PD20); 
b
vs age ≤ 26 years; cvs non-smoking; dvs Autumn; evs normal weight subjects; fadjusted for 
age, smoking, FEV1, FVC and seasons. 
Table 6 Logistic binary regression model to evaluate the risk of the various considered covariates in females with different levels of 
airways hyperresponsiveness (compared to normal subjects) 
 All AHR subjects
a
 Mild AHR
a
 Moderate AHR
a
 Severe AHR
a
 
 OR 95 % CI p OR 95 % CI p OR 95 % CI P OR 95 % CI p 
Aged 27–44 yearsb 0.775 0.569-1.057 0.107 0.899 0.600-1.346 0.604 0.753 0.506-1.121 0.163 0.611 0.398-0.939 0.025 
Age ≥ 45 yearsb 0.589 0.423-0.819 0.002 0.766 0.496-1.181 0.227 0.558 0.364-0.854 0.007 0.406 0.253-0.651 0.0001 
Smoking
c
 1.609 1.243-2.081 0.0001 1.414 1.014-1.973 0.041 1.750 1.278-2.397 0.0001 1.767 1.229-2.540 0.002 
FEV1% of predicted 0.925 0.912-0.939 0.0001 0.957 0.938-0.976 0.0001 0.928 0.910-0.946 0.0001 0.873 0.853-0.894 0.0001 
FVC % of predicted 1.055 1.039-1.070 0.0001 1.029 1.009-1.049 0.003 1.061 1.041-1.080 0.0001 1.085 1.062-1.109 0.0001 
Winter
d
 0.645 0.491-0.847 0.002 0.613 0.431-0.872 0.007 0.674 0.478-0.950 0.024 0.662 0.447-0.981 0.040 
Spring
d
 0.717 0.541-0.949 0.020 0.585 0.403-0.849 0.005 0.810 0.572-1.147 0.235 0.829 0.557-1.236 0.358 
Summer
d
 0.624 0.469-0.830 0.001 0.681 0.476-0.976 0.036 0.662 0.462-0.949 0.025 0.524 0.340-0.807 0.003 
Underweight
ef
 1.012 0.568-1.805 0.967 1.222 0.611-2.443 0.571 0.774 0.340-1.766 0.543 0.895 0.390-2.055 0.793 
Overweight
ef
 1.178 0.919-1.509 0.195 1.042 0.752-1.444 0.805 1.297 0.947-1.777 0.104 1.338 0.929-1.928 0.118 
Obese
ef
 1.247 0.937-1.661 0.130 0.856 0.578-1.268 0.439 1.741 1.226-2.471 0.002 1.235 0.806-1.894 0.333 
Subjects with AHR = PD20 < 3200 μg; Severe AHR = PD20 ≤ 200 μg; moderate AHR = PD20 > 200 and ≤ 800 μg; mild AHR = PD20 > 800 μg; 
a
vs subjects with normal reactivity (without PD20); 
bvs age ≤ 26 years; cvs non-smoking; dvs Autumn; evs normal weight subjects; fadjusted for 
age, smoking, FEV1, FVC and seasons. 
In the attempt to find also a possible relationship between BMI and pulmonary function, we applied a regression linear model associating BMI 
and baseline lung function, adjusted for age, season and smoking habit (Table 7). Both in males and females, a relationship was found between 
BMI and FEV1/FVC in the entire group and in subjects with moderate AHR. In the latter, a significant reduction of FEV1/FVC for unit of BMI 
increase was found both in males (β = −0.255; p = 0.023) and females (β = −0.451; p = 0.017). No significant relationships between BMI and 
FEV1/FVC were found, either in males or females, both with severe AHR and normal bronchial response to Mch. 
 
 
Table 7 Relations between lung function and BMI (regression linear model) corrected for age, season and smoking habits 
 All AHR subjects Mild AHR Moderate AHR Severe AHR Normal 
 Males Females Males Females Males Females Males Females Males Females 
 β p β p β p β p β p β p β p β p β p β p 
FVC% −0.062 0.110 −0.155 0.004 −0.091 0.200 −0.071 0.437 −0.229 0.022 −0.388 0.011 −0.006 0.938 −0.102 0.537 −0.027 0.712 −0.183 0.037 
FEV1% 0.064 0.092 0.132 0.015 0.069 0.330 0.037 0.689 0.228 0.021 0.371 0.014 0.028 0.717 0.100 0.537 0.027 0.712 0.152 0.081 
FEV1/FVC −0.118 0.009 −0.173 0.01 −0.177 0.049 −0.094 0.416 −0.255 0.023 −0.451 0.017 −0.044 0.623 −0.066 0.733 −0.105 0.220 −0.206 0.062 
Age 0.075 0.0001 0.122 0.0001 0.051 0.012 0.140 0.0001 0.098 0.0001 0.090 0.0001 0.065 0.002 0.114 0.0001 0.074 0.0001 0.128 0.0001 
Seasons 0.042 0.551 0.050 0.613 0.229 0.167 −0.131 0.566 −0.037 0.820 0.294 0.155 −0.001 0.996 −0.277 0.193 0.032 0.757 0.100 0.541 
Smoking −0.345 0.074 −0.917 0.001 −0.743 0.093 −1.251 0.054 −0.055 0.893 −0.835 0.139 −0.516 0.289 −0.656 0.267 −0.338 0.248 −1.147 0.027 
Constant 32.22 0.0001 37.27 0.0001 40.00 0.0001 31.40 0.004 43.61 0.0001 62.22 0.0001 24.65 0.002 27.30 0.120 30.47 0.0001 40.32 0.0001 
Subjects with AHR = PD20 < 3200 μg; Severe AHR = PD20 ≤ 200 μg; moderate AHR = PD20 > 200 and ≤ 800 μg; mild AHR = PD20 > 800 μg. 
Normal = subjects with normal reactivity (without PD20). 
Discussion 
The current study was performed with the aim of exploring the relationship between BMI and 
AHR in a large cohort of male and female adults with suspected asthma. Overall, the 
proportion of hyperresponsive subjects did not differ with body weight in the population 
tested. Similarly, the level of AHR was equally distributed among the body weight groups. 
However, an interesting bi-modal behaviour emerged in females with moderate degree of 
AHR: a “protective” effect of body weight in the underweight condition and a “detrimental” 
effect of body weight in the obese state, thus describing an imaginary inverted U-shape curve 
of the relationship between BMI and PD20. These findings suggest that the influence of the 
adipose tissue on airway function should be further investigated in the moderate 
hyperresponsive female phenotype. 
Our results are in line with some studies [18,19] that did not find any difference in PD20 
values in obese and normal-weight asthmatics, and differ from those observed in the study of 
Schachter et al. [8], who found an increase in AHR in underweight subjects, although no 
plausible explanations were provided. Our results in the underweight subgroup are 
conflicting. In fact, in underweight females with moderate AHR, a significant positive 
correlation was found between BMI and PD20 which allowed us to infer that increasing 
weight might reduce the degree of AHR in these subjects. Therefore, the underweight 
condition in females seems to be a risk factor for AHR even though the logistic regression 
model did not confirm such a risk. On the contrary, the underweight condition in males seems 
to be a protective factor for AHR, probably due to hormonal differences. 
In addition, our study showed that BMI (adjusted for age, pulmonary function, smoking and 
seasons) was an AHR risk factor in females but not in males. In fact, the obese status in 
females was an important AHR risk factor only when subjects with moderate levels of AHR 
were considered. Like other investigators, we could not find the expected relationship 
between BMI and PD20 in subjects with severe AHR, [20]. In fact, they found that obesity in 
asthmatic patients is negatively correlated to the intensity of AHR and not to asthma severity. 
This could be explained by the fact that in most severe stages, AHR is mainly characterized 
by a non-reversible component, probably associated with airway structural changes. 
The observed different behaviours between sexes can already be found in literature. In fact, 
other studies showed differences between sexes with regard to the influence of BMI on AHR 
[2,4,6,7,12,13], with a more pronounced association in females [2,13,21,22]. It is plausible 
that sexual hormones, and in particular estrogens, may play a role in modulating the 
relationship between BMI and asthma. In obesity, the production of estrogens is generally 
increased and is associated with early menarche in women and delay in the onset of puberty 
in men. Some authors demonstrated that the prevalence of asthma, the association between 
BMI and the severity of the disease were greater in women with early menarche [23,24]. 
Furthermore, estrogens and progesterone may modify the inflammatory response to favour a 
Th2 response [1]. In this respect, β-estradiol enhances eosinophil adhesion to human mucosal 
microvascular endothelial cells and induces degranulation (unlike the testosterone effect), 
whereas progesterone increases bronchial eosinophilia and enhances bronchial 
responsiveness [25,26]. Another explanation may lie in the different abdominal fat 
distribution in males and females. In the latter, there is a greater subcutaneous fat distribution, 
whereas in males a higher visceral adipose tissue is observed. Interestingly, the subcutaneous 
abdominal fat appears to increase the risk of hyperresponsiveness, whereas visceral 
abdominal fat is not associated with AHR [27]. Furthermore, gynoid fat mass was associated 
with higher degrees of hyperrresponsiveness after an hypertonic saline challenge test in 
females [13]. Likely, the higher leptin production from subcutaneous fat rather than visceral 
fat, with greater values in females compared with males, may be the cause of a more serious 
status of asthma in obese women [1,28]. Leptin may activate or increase the airway 
inflammation in asthmatics [1,2,12,29]; in fact, a relationship between circulating leptin 
levels and risk of asthma development was observed in females [29]. Recently, an increase in 
neutrophilic airways inflammation in obese female asthmatics was documented in a study 
[12]. Another study showed that a gynoid fat mass is associated with a lower concentration of 
airway eosinophils in females [13]. Therefore, the different influence of BMI on AHR could 
be due to a different inflammatory pattern induced by obesity in males and females. Likely, a 
higher production of leptin from subcutaneous adipose tissue, which is typical of females, 
promotes T-helper type 1 cell differentiation and increases activation of neutrophils via 
tumour necrosis factor α [30]. 
The alternative explanation for our findings could be a pure mechanical factor, as 
demonstrated by the influence of the reduction in the FEV1/FVC ratio for unit of BMI 
increase (obstructive pattern). An excess soft tissue weight compressing the thoracic cage, a 
fatty infiltration of chest wall and an increase in pulmonary blood volume, might contribute 
to determine a reduction in lung volumes for a mechanical effect especially in females 
[2,20,31]. This is associated with an impairment in the lung inflation-induced airway 
distensibility and a reduction in airway peripheral diameter, which, over time, alter smooth 
muscle function thus increasing both airway obstruction and consequently AHR [1]. In our 
study, the FEV1 increase was a protective factor for AHR in both sexes, therefore suggesting 
that a reduction of lung function may favour AHR. It is likely that the already smaller calibre 
of airways in females may be influenced by BMI-induced obstruction in a more pronounced 
fashion than in males. This is supported by other studies who also observed a greater effect of 
adipose tissue on females’ lung function compared with males’ [13,32]. 
Another interesting result of this study, as already pointed out, is the different relationship 
between BMI and AHR at various levels of AHR (mild, moderate and severe) in females. 
The absence of any associations between BMI and mild AHR is certainly due to the fact that 
a great proportion of subjects belonging to this group did not result asthmatics. In fact, high 
values of PD20 or PC20, in case of suspected asthma (as in our patients), make an asthma 
diagnosis less probable [16]. It is difficult to explain why BMI and AHR are associated only 
in moderate hyperresponsive females and not in severe AHR. The factors that contribute to 
AHR may be divided into two categories: persistent and variable [33]. The airway structural 
changes (i.e. sub-endothelial and sub-basement membrane thickening, smooth muscle 
hypertrophy, matrix deposition, and altered vascular components - due to the chronic and 
long standing airway inflammation) represent persistent alterations [33]. On the other hand, 
the variable AHR component is believed to relate to inflammatory airway events, which may 
vary and be influenced by numerous environmental events (ie, allergens, respiratory 
infections and treatment) [16]. It is logical to hypothesize that these two components are 
interrelated. Obesity is a chronic inflammatory state [1,2] and may have a variable 
component role in the bronchial hyperreactivity mechanism. In fact, neutrophilic airways 
inflammation is increased by obesity and fatty acids in asthma [12]. Similarly, weight loss, 
through bariatric surgery, produces significant reductions in exhaled nitric oxide 
concentrations in obese asthmatic patients [34]. Proinflammatory molecules, expressed by 
adipose tissue such as leptin, TNF-α, IL-6, TGF- β1, adiponectin and C-reactive protein, 
increase in obese subjects [1,2,12], especially in females (above all C-reactive protein and 
leptin) [13]. These obesity factors may interfere with persistent AHR mechanisms and they 
may be greater in severe than in moderate AHR. In fact, the exhaled nitric oxide level 
significantly increases with the increasing of the AHR level in asthmatics [35,36]. Patients 
with intermittent asthma also showed airway inflammation but to a lower extent than those 
with persistent asthma [37]. Therefore, the supposed additional effects of inflammatory 
components, due to obesity (variable component), may have a lower impact in subjects with 
severe AHR because they have already a basal high level of asthma induced-inflammation 
(persistent component). On the other hand, basal airway inflammation may be less extensive 
in subjects with moderate AHR and therefore the variable inflammatory effect of weight may 
be greater, thus influencing AHR. In other words, systemic inflammation (BMI-induced) 
might influence airways inflammation only in asthma mild forms, whereas this influence 
might be trivial in more severe asthmatics. The fact that we could not find any relationships 
between BMI and pulmonary function in females with severe AHR strengthens our 
hypothesis. 
Obesity may influence AHR in females with moderate hyperresponsiveness through a greater 
bronchial obstruction (reduced FEV1/FVC for unit of BMI increase). Reduction in FEV1/FVC 
was also found both in obese children [7] and adults [20], but not confirmed by Scott et al. 
[13]. This low level of FEV1/FVC may be a consequence of a systemic inflammation induced 
by adipose tissues or simply the mechanical effect of weight. When AHR becomes severe, 
the relationship between BMI and pulmonary function disappears so that we may hypothesize 
that the factors responsible for AHR may be only due to airway inflammation but probably 
not to systemic BMI induced inflammation and probably not to mechanical induced 
obstruction either. 
Conclusions 
In conclusion, obesity can influence airway hyperresponsiveness only in females and only 
when the AHR level is moderate. No effects of BMI were found in males and in severe AHR. 
This BMI-induced influence may be mediated by a greater airway obstruction, probably due 
to a systemic inflammation or a purely weight associated mechanical effect. 
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